The study aimed to assess the prevalence and characteristics of potential drug-drug interactions (pDDIs) that increase the risk of QT prolongation, in a population of cardiovascular disease patients.

“The Year 2 jump” is practically cliché in NFL circles. The Packers’ season might depend on Matthew Golden becoming a star in ...

A 70-year-old woman presents to the ED with chest pain, shortness of breath and diaphoresis. Her symptoms began about 24 ...

Nuvation Bio , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in ...

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML ...

The National Association of Women in Construction Las Vegas recently launched a new scholarship in partnership with trade ...

ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or ...

High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, ...

- Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations - - Ph 1 trial of revumenib with ...

- High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) - - Strong activity across subgroups ...

Acquired long QT syndrome (aLQTS) is a disorder of delayed myocardial repolarization induced by medications, electrolyte disturbances, and other factors, with a significantly higher risk in females ...

– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90% ...